2024 Run The Check


21 runners. 200+ miles. 36 hours. This Giving Tuesday, you have the opportunity to help Run the Check and double-the-donation of our MS research grant to the University of Arkansas-Little Rock (UAMS) from $32,500 to $65,000.

About the Rampy MS Research Foundation

MS stops people from moving. We are moving towards a cure. 

  • Nearly 1 million people are living with multiple sclerosis (MS) in the United States.
  • MS is also the leading cause of disability among young adults.
  • We’re building a first-of-its-kind research network focused exclusively on a cure with the top research scientists in the country. 

While this effort funds MS research at the University of Arkansas-Medical Sciences. The Foundation also funds MS research at Northwestern University and the University of California-San Francisco. 

Scientists tell us we are closer than ever to finding a cure for multiple sclerosis (MS). It's simply a matter of how quickly we can fund it. Join us. 

Help Get the Word Out

Tune in this #GivingTuesday. Follow the runners across the state, hear stories for what this research means to the multiple sclerosis community and be encouraged along the way.    

FAQs

How many people have MS? 

Nearly 1 million people are living with multiple sclerosis in the United States. MS is also the leading cause of disability among young adults, usually appearing between ages 20 and 40.

How are you advancing MS research?

With guidance from our Medical Review Board, we are building a first-of-its-kind research network focused on exclusively on a cure with the top MS research scientists in the country. This network currently includes University of Arkansas-Medical Sciences (UAMS), Northwest University and the University of California-San Francisco.

Will your employer match your donation?

More than 26 million people work for an employer that will match an donation of an employee, employee's spouse and/or retiree. Search our database to see if your employer will help you double (or triple!) your impact. 

Funding a Cure for Multiple Sclerosis: Our Story